New-generation cell-penetrating peptides overcome earlier limitations with improved cell selectivity, protease stability, and endosomal escape, enabling drug delivery across barriers like skin, the blood-brain barrier, and eye tissues.
3 biological barriers crossedNew-generation CPPs can penetrate skin, the blood-brain barrier, and eye tissues — potentially replacing injections with non-invasive sprays, creams, and drops.
What the researchers found
New-generation CPPs address three major limitations of earlier peptides:
1. **Cell selectivity**: Hybrid designs combine homing sequences for tissue targeting with activation sequences that only work at the target site, dramatically improving specificity.
2. **Protease stability**: Conjugation to nanoparticles and structural modifications protect CPPs from enzymatic degradation in the body.
3. **Endosomal escape**: Engineered sequences enable CPPs to break out of endosomes (cellular compartments that trap delivered cargo), ensuring drugs actually reach their intracellular targets.
Several naturally tumor-selective CPPs were highlighted — azurin, crotamine, maurocalcine, lycosin-I, buffalo cathelicidin, and peptide CB5005 — which can both penetrate cancer cell membranes and directly exert cytotoxic effects through intracellular signaling pathways.
Notably, certain CPPs can now penetrate the blood-brain barrier, skin, and eye tissues, enabling non-invasive delivery via sprays, creams, and drops instead of injections.
Why it matters
Getting drugs to the right cells inside the body remains one of medicine's biggest challenges. Most large therapeutic molecules (proteins, nucleic acids, antibodies) cannot cross cell membranes on their own. CPPs that can selectively deliver these cargoes to tumor cells, across the blood-brain barrier, or through skin could transform treatment for cancer, neurological diseases, and eye conditions — while making treatment less invasive and more patient-friendly.
The numbers in context
CPPs covered: azurin, crotamine, maurocalcine, lycosin-I, cathelicidin, CB5005; barriers: skin, BBB, eye; delivery: nanoparticle conjugation, sprays, creams, drops
How the study worked
This is a narrative review of recent literature on next-generation cell-penetrating peptides. It covers CPPs derived from natural sources (venoms, bacterial proteins, cathelicidins) as well as rationally designed hybrid structures. The review discusses mechanisms of cell entry, nanoparticle conjugation strategies, barrier-crossing capabilities, and 3D tissue penetration for tumor treatment.
Who was studied
Review of literature on next-generation cell-penetrating peptides
What this study cannot tell us
This is a review article that does not generate new experimental data. Most CPPs discussed remain in preclinical development. Comparing CPP efficacy is inherently difficult because performance depends on the specific cargo, target tissue, coupling method, and experimental conditions. Clinical translation faces challenges including manufacturing scalability, immunogenicity, and regulatory approval of novel delivery systems.
How to read the evidence
This is a narrative review synthesizing preclinical research on cell-penetrating peptides. While it provides a comprehensive overview of the field, it does not present new data and most technologies discussed are still in early development stages.
When this study was published
Published in 2021, this review captures the state of CPP technology at a time of rapid advancement. The field has continued to evolve, with new designs and clinical applications emerging since publication.
The bigger picture
Cell-penetrating peptides represent a convergence of peptide science, nanotechnology, and drug delivery engineering. As biologics (proteins, antibodies, gene therapies) become an ever-larger share of the drug pipeline, the need for efficient intracellular delivery systems grows. New-generation CPPs that can target specific tissues and cross biological barriers could enable therapies that are currently impossible — particularly for brain diseases where the blood-brain barrier blocks most drugs.
Questions still open
- Which of these new-generation CPPs are closest to clinical application, and what are the remaining barriers to human use?
- Can CPP-mediated blood-brain barrier crossing deliver therapeutic concentrations of drugs for neurological diseases?
- How will regulatory frameworks adapt to evaluate these novel peptide-based drug delivery systems?
Common questions
What are cell-penetrating peptides?
Could CPPs replace needles for drug delivery?
Read the original research
New generation of cell-penetrating peptides: Functionality and potential clinical application.
Journal of peptide science : an official publication of the European Peptide Society, 27(5), e3300
Citation
Reissmann, Siegmund; Filatova, Margarita P. (2021). New generation of cell-penetrating peptides: Functionality and potential clinical application.. Journal of peptide science : an official publication of the European Peptide Society, 27(5), e3300. https://doi.org/10.1002/psc.3300